Kosan BioSciences -- KOSN Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Kosan BioSciences -- KOSN

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who started this subject	7/3/2001 7:21:28 AM
From: dalroi	Read Replies (1) of 933

lets rock Tuesday July 3, 7:02 am Eastern Time Press Release Kosan Collaborator Finds Epothilone D to be Superior to Paclitaxel in Animal Models Head-to-Head study published in The Proceedings of the National Academy of Sciences HAYWARD, Calif.--(BW HealthWire)--July 3, 2001--Kosan Biosciences Incorporated (Nasdaq:KOSN - news) announced today the publication of extensive experiments by its collaborators at the Sloan-Kettering Institute for Cancer Research indicating that Epothilone D is an efficacious anti-tumor agent with a broad therapeutic spectrum and wide safety margin in animal model systems. In this head-to-head study, it was demonstrated that the therapeutic effects of Epothilone D are superior to paclitaxel as well as some other currently used cancer therapeutics. Paclitaxel is the active ingredient in the leading anticancer agent Taxol®.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next